| Autor: |
Tegan K. Boehmer, Emily H. Koumans, Elizabeth L. Skillen, Michael D. Kappelman, Thomas W. Carton, Aditiben Patel, Euna M. August, Ryan Bernstein, Joshua L. Denson, Christine Draper, Adi V. Gundlapalli, Anuradha Paranjape, Jon Puro, Preetika Rao, David A. Siegel, William E. Trick, Chastity L. Walker, Jason P. Block |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
MMWR. Morbidity and mortality weekly report. 71(43) |
| ISSN: |
1545-861X |
| Popis: |
In December 2021 and early 2022, four medications received emergency use authorization (EUA) by the Food and Drug Administration for outpatient treatment of mild-to-moderate COVID-19 in patients who are at high risk for progressing to severe disease; these included nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) (both oral antivirals), expanded use of remdesivir (Veklury; an intraveneous antiviral), and bebtelovimab (a monoclonal antibody [mAb]).* Reports have documented disparities in mAb treatment by race and ethnicity (1) and in oral antiviral treatment by zip code-level social vulnerability (2); however, limited data are available on racial and ethnic disparities in oral antiviral treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
